Elos Medtech Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Elos Medtech.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	36.6%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

The President & CEO of Elos Medtech AB (publ) (STO:ELOS B), Jan Wahlström, Just Bought 28% More Shares

Feb 28

Do Fundamentals Have Any Role To Play In Driving Elos Medtech AB (publ)'s (STO:ELOS B) Stock Up Recently?

Feb 24

Elos Medtech (STO:ELOS B) Has Gifted Shareholders With A Fantastic 102% Total Return On Their Investment

Feb 11

When Should You Buy Elos Medtech AB (publ) (STO:ELOS B)?

Jan 31

How Much Are Elos Medtech AB (publ) (STO:ELOS B) Insiders Taking Off The Table?

Jan 18

Returns On Capital At Elos Medtech (STO:ELOS B) Paint An Interesting Picture

Jan 06

Could The Elos Medtech AB (publ) (STO:ELOS B) Ownership Structure Tell Us Something Useful?

Dec 26

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Dec 13

Here's Why We Don't Think Elos Medtech's (STO:ELOS B) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 30

Elos Medtech AB (publ)'s (STO:ELOS B) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 17

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Elos Medtech n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OM:ELOS B - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2023	1,018	55	-52	95	N/A
6/30/2023	998	55	-1	121	N/A
3/31/2023	961	76	-7	113	N/A
12/31/2022	889	75	-9	108	N/A
9/30/2022	843	94	7	123	N/A
6/30/2022	799	90	-17	81	N/A
3/31/2022	747	79	11	89	N/A
12/31/2021	724	76	19	105	N/A
9/30/2021	694	67	14	96	N/A
6/30/2021	655	62	45	125	N/A
3/31/2021	592	51	55	141	N/A
12/31/2020	580	36	69	126	N/A
9/30/2020	584	33	74	116	N/A
6/30/2020	593	29	43	105	N/A
3/31/2020	658	29	20	102	N/A
12/31/2019	689	39	4	102	N/A
9/30/2019	700	35	-4	107	N/A
6/30/2019	697	32	-12	95	N/A
3/31/2019	679	29	-21	67	N/A
12/31/2018	645	21	-14	66	N/A
9/30/2018	625	24	-12	66	N/A
6/30/2018	603	21	0	58	N/A
3/31/2018	593	23	12	59	N/A
12/31/2017	578	23	25	62	N/A
9/30/2017	562	18	40	68	N/A
6/30/2017	556	23	N/A	86	N/A
3/31/2017	552	29	N/A	90	N/A
12/31/2016	552	26	N/A	98	N/A
9/30/2016	555	27	N/A	95	N/A
6/30/2016	551	20	N/A	74	N/A
3/31/2016	539	15	N/A	71	N/A
12/31/2015	504	16	N/A	63	N/A
9/30/2015	474	17	N/A	120	N/A
6/30/2015	436	23	N/A	181	N/A
3/31/2015	398	26	N/A	196	N/A
12/31/2014	381	23	N/A	175	N/A
9/30/2014	371	25	N/A	120	N/A
6/30/2014	369	18	N/A	94	N/A
3/31/2014	366	17	N/A	75	N/A
12/31/2013	368	17	N/A	80	N/A
9/30/2013	396	20	N/A	82	N/A
6/30/2013	413	18	N/A	51	N/A
3/31/2013	424	12	N/A	46	N/A
12/31/2012	434	8	N/A	39	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de ELOS B est supérieure au taux d'épargne ( 0.8% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de ELOS B devraient croître plus rapidement que le marché Swedish

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de ELOS B devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de ELOS B devraient croître plus rapidement que le marché Swedish.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de ELOS B devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ELOS B devrait être élevé dans 3 ans

Elos Medtech Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Elos Medtech AB (publ) (OM:ELOS B) acquired Klingel Holding GmbH from IK Partners and Management.

Nasdaq Stockholm Approves Elos Medtech's Application for De-Listing

Elos Medtech Applies for De-Listing from Nasdaq Stockholm

New major risk - Shareholder dilution

Elos Medtech AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Third quarter 2023 earnings released

Elos Medtech AB (publ) (OM:ELOS B) entered an agreement to acquire KLINGEL medical metal GmbH from IK Partners and Management for an enterprise value of €370 million.

New minor risk - Profit margin trend

Second quarter 2023 earnings released

Investor sentiment improves as stock rises 20%

Elos Medtech AB (Publ) Elects Winfried Schaller as Board Member

First quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr9.31 (vs kr9.37 in FY 2021)

No independent directors

Elos Medtech AB (publ) to Report Q3, 2023 Results on Oct 19, 2023

Third quarter 2022 earnings released

Elos Medtech AB Announces Nomination Committee Appointments

Elos Medtech AB (Publ) Announces Management Changes

Elos Medtech AB (Publ) Announces Management Changes

Second quarter 2022 earnings released

Elos Medtech AB (publ) Omits Dividend for the Year 2021

First quarter 2022 earnings: Revenues miss analyst expectations

Less than half of directors are independent

Elos Medtech AB (publ)(OM:ELOS B) dropped from OMX Nordic Small Cap Index

Chief Financial Officer recently sold kr159k worth of stock

Chief Financial Officer recently sold kr159k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Elos Medtech AB (publ) (STO:ELOS B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Independent Director recently sold kr848k worth of stock

Second quarter 2021 earnings released: EPS kr2.28 (vs kr0.85 in 2Q 2020)

TA Associates Management, L.P. through its funds Ta Xiii-B, L.P., Ta Xiii-A, L.P. and TA Investors XIII, L.P. made an offer to acquire Elos Medtech AB (publ) (OM:ELOS B) from a group of sellers for SEK 1.7 billion.

Elos Medtech in Talks of Possible Takeover Bid

Is Now The Time To Look At Buying Elos Medtech AB (publ) (STO:ELOS B)?

Here's Why I Think Elos Medtech (STO:ELOS B) Is An Interesting Stock

First quarter 2021 earnings released

Upcoming dividend of kr1.50 per share

Returns On Capital Are Showing Encouraging Signs At Elos Medtech (STO:ELOS B)

We Think Elos Medtech (STO:ELOS B) Is Taking Some Risk With Its Debt

President & CEO recently sold kr801k worth of stock

Should Elos Medtech AB (publ) (STO:ELOS B) Be Part Of Your Dividend Portfolio?

New 90-day high: kr121

The President & CEO of Elos Medtech AB (publ) (STO:ELOS B), Jan Wahlström, Just Bought 28% More Shares

President & CEO recently bought kr233k worth of stock

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS kr4.46 (vs kr4.77 in FY 2019)

Do Fundamentals Have Any Role To Play In Driving Elos Medtech AB (publ)'s (STO:ELOS B) Stock Up Recently?

Elos Medtech (STO:ELOS B) Has Gifted Shareholders With A Fantastic 102% Total Return On Their Investment

New 90-day high: kr117

When Should You Buy Elos Medtech AB (publ) (STO:ELOS B)?

How Much Are Elos Medtech AB (publ) (STO:ELOS B) Insiders Taking Off The Table?

Elos Medtech AB (publ) Announces Executive Changes

Returns On Capital At Elos Medtech (STO:ELOS B) Paint An Interesting Picture

New 90-day high: kr109

Could The Elos Medtech AB (publ) (STO:ELOS B) Ownership Structure Tell Us Something Useful?

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Here's Why We Don't Think Elos Medtech's (STO:ELOS B) Statutory Earnings Reflect Its Underlying Earnings Potential

Elos Medtech AB (publ)'s (STO:ELOS B) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

New 90-day high: kr98.80

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

Elos Medtech AB (publ) to Report Q3, 2021 Results on Oct 20, 2021

New 90-day high - kr89.60

New 90-day high - kr77.20

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance